Former 510(k) Staff Director Takes Critical Look At FDA's Reform Plan
This article was originally published in The Gray Sheet
Executive Summary
As FDA rolls out changes to its 510(k) review process, Heather Rosecrans, former director of the 510(k) program staff, and now on the industry side of the debate, is watching with keen interest and some trepidation.
You may also be interested in...
FDA Says Some Notice-To-Industry Letters Will Be Level 1 Guidance
FDA says some of its new "notice-to-industry" letters will have the same force as agency guidance documents that take effect immediately.
FDA Says Some Notice-To-Industry Letters Will Be Level 1 Guidance
FDA says some of its new "notice-to-industry" letters will have the same force as agency guidance documents that take effect immediately.
To Speed Guidance Development, CDRH Will Need More Resources – Shuren
FDA's device center wants to improve the predictability of its product review process with more guidance documents, but lacks the personnel and resources to fully deliver, according to center director Jeffrey Shuren.